Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies Generic price competition is viewed as an important way to contain prices and increase patient access to prescription medications.1,2 Following the introduction of generic options, substantial decreases have been observed in prices for infused anticancer therapies. However, it is unclear whether such declines will be observed for orally administered anticancer drugs.3 Capecitabine is one of the first high-priced orally administered anticancer drugs to lose patent protection in the United States, making it a useful case study for understanding how generic entry may affect orally administered anticancer drug prices.

中文翻译：

---

通用价格竞争可能不足以控制口服抗癌药物的价格

仿制药价格竞争可能不足以控制口服抗癌疗法的价格 仿制药价格竞争被视为控制价格和增加患者获得处方药机会的重要方式。 1,2 在引入仿制药后，观察到大幅下降输注抗癌疗法的价格。然而，目前尚不清楚口服抗癌药物是否会出现这种下降。3 卡培他滨是美国第一个失去专利保护的高价口服抗癌药物之一，使其成为了解仿制药的有用案例研究进入可能会影响口服抗癌药物的价格。